Zsiros E, Lynam S, Attwood KM, et al. - Researchers undertook this open-label, single-arm phase 2 cohort study to test a combination of pembrolizumab with bevacizumab and oral metronomic cyclophosphamide in terms of effectiveness and safety in the treatment of recurrent platinum-sensitive, platinum-resistant, or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer. Eligible patients were given intravenous pembrolizumab, 200 mg, and bevacizumab, 15 mg/kg, every 3 weeks and oral cyclophosphamide, 50 mg, once daily during the treatment cycle until disease advancement, unacceptable toxic impacts, or withdrawal of consent. Findings of this nonrandomized clinical trial demonstrated good tolerability of the combination of pembrolizumab with bevacizumab and oral cyclophosphamide as well as the effectiveness of this treatment regimen in affording clinical advantage in 95.0% and durable treatment responses (> 12 months) in 25.0% of patients suffering from recurrent ovarian cancer. This combination may be a future therapeutic approach for recurrent ovarian cancer.